WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders

NEW YORK, Oct. 13, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Dimension Therapeutics, Inc. ("DMTX" or the "Company") (NASDAQ: DMTX) in connection with the proposed acquisition of the Company by Ultragenyx Pharmaceutical Inc. ("RARE") (NASDAQ: RARE).  On October 2, 2017, the Company issued a press release announcing its acceptance of RARE's "superior proposal" and the signing of a definitive agreement under which terms RARE will acquire all outstanding shares of DMTX in a transaction valued at approximately $151.00 million, offering DTMX shareholders $6.00 for each share they own. 

WeissLaw is investigating whether DMTX's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $9.00 per share, or $3.00 above the offer price. 

Further, according Emil D. Kakkis, RARE's President and CEO, "[t]he acquisition [] provides a unique opportunity to approach treatment of more rare diseases and advance [RARE's] development as a next generation rare disease company."  The deal will grant RARE access to DTMX's technology platform which will expand RARE into new therapeutic modalities and capabilities, and diversifies its clinical and preclinical pipeline. 

Given these facts, WeissLaw is investigating whether DMTX's Board acted in the best interests of DMTX's public shareholders to maximize shareholder value prior to entering into the agreement.  If you own DMTX shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Joshua Rubinby telephone at (888) 593-4771 or by email at stockinfo@weisslawllp.com.  

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.comor fill out the form on our website, http://www.weisslawllp.com/dimension-therapeutics-inc/

View original content:http://www.prnewswire.com/news-releases/weisslaw-llp-dimension-therapeutics-inc-acquisition-may-not-be-in-the-best-interests-of-dmtx-shareholders-300536453.html

SOURCE WeissLaw LLP